Chile

Number of regulators formally agreeing to work toward creating Latin American regulator is growing.

The number of regulators formally agreeing to work towards creating a Latin American regulator is growing.

Medicines regulators from Mexico, Colombia and Cuba have pledged to create a new agency for medicines and medical devices of Latin America and the Caribbean.

CHAP’s Brian Green is Association TRENDS 2022 Association CFO of the Year; “Matisse-like dreamscape” In Olive Natural Packaging redesign; NIH’s ODS wants strategic plan input; and IFF innovation centers in Brazil, Chile, Colombia.

Gedeon Richter and Mithra have expanded their partnership on an in-development contraceptive, Estelle, to cover several Latin American territories on top of Europe and Russia.

Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

A recent survey commissioned by the Latin American Alliance for Responsible Nutrition (ALANUR) shows almost half of urbanites in Chile and Peru used dietary supplements in the last three months.

Latin American countries are continuing to pursue a strategy of jointly negotiating medicine prices to get a better deal on expensive medicines. However, manufacturers have expressed doubt that this is the best way forward.

A bill which would have allowed OTC drugs to be sold outside pharmacies in Chile has been scuppered by the country's National Congress. 

Medicines regulators from the Pacific Alliance have taken a step towards greater regional regulatory harmonization in a bid to make registration of medicines faster.

Generic competition is nearing for hepatitis C medicines formulated with Gilead’s sofosbuvir in Chile, following moves by the health ministry to allow compulsory licensing.

Generic competition is nearing for hepatitis C medicines formulated with Gilead’s sofosbuvir in Chile, following moves by the health ministry to allow compulsory licensing.

Chile’s lower house of congress has backed a resolution calling for the government to set the scene for the compulsory licensing of hepatitis C drugs.

Chile’s lower house of congress has backed a resolution calling for the government to set the scene for the compulsory licensing of hepatitis C drugs.

Pressure is mounting in Chile for the government to pursue compulsory licensing. Gilead’s Sovadi (sofosbuvir) and Astellas’s prostate cancer drug Xtandi (enzalutamide) could be among the drugs eventually opened up to generic competition.

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

The FDA on 23 January cleared the way for Novartis to market its much-anticipated meningitis B vaccine Bexsero, which is approved for use in Americans 10-25 years.